Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

Summary

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation. The hypothesis is that clinical differences in course of disease reflect underlying biological characteristics.

Timeline

Start

2020-05-11

Primary completion

2025-05-01

Completion

2033-05-01

Publications

• Horndalsveen H, Haakensen VD, Madebo T, Gronberg BH, Halvorsen TO, Bjaanaes MM, Danielsen BK, Borve M, Kokkvoll S, Boda TSD, Ojlert AK, Helland A. ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab. J Thorac Oncol. 2026 Jun 23:103992. doi: 10.1016/j.jtho.2026.103992. Online ahead of print.
• Horndalsveen H, Haakensen VD, Madebo T, Gronberg BH, Halvorsen TO, Koivunen J, Oselin K, Cicenas S, Helbekkmo N, Aanerud M, Ahvonen J, Silvoniemi M, Bjaanaes MM, Farooqi S, Nebdal D, Dalsgaard AM, Danielsen BK, Borve M, Dalen TS, Ojlert AK, Helland A. Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab. Front Oncol. 2025 Oct 22;15:1681420. doi: 10.3389/fonc.2025.1681420. eCollection 2025.
• Langberg CW, Horndalsveen H, Helland A, Haakensen VD. Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC. Front Oncol. 2023 Jul 5;13:1217424. doi: 10.3389/fonc.2023.1217424. eCollection 2023.

Drugs

Indications